Basic Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Jul 14, 2020; 26(26): 3737-3749
Published online Jul 14, 2020. doi: 10.3748/wjg.v26.i26.3737
Figure 2
Figure 2 The combination of PT1001B and programmed death-ligand-1 blockade inhibits the development of pancreatic ductal adenocarcinoma in mice. Panc02 cells were surgically transplanted into C57BL/6 mice. One week later, tumors reached approximately 100 mm3, and tumor-bearing mice were randomly divided into four groups that were treated with PT1001B (30 mg/kg body weight, once daily) or anti- programmed death-ligand-1 (PD-L1) mAb (200 μg/mouse, every 2 d for 5 intervals) alone or in combination via intraperitoneal injection for 37 d. A: The combination of PT1001B and anti-PD-L1 mAb significantly inhibited tumor growth; B: Tumors in different treated groups; C: Mouse body weight curve. The values were analyzed by one-way ANOVA. Data represent the mean ± SE (n = 4). aP < 0.05, bP < 0.01 vs control group. PD-L1: Programmed death-ligand-1.